|1.||Mitchison, Timothy J: 3 articles (10/2013 - 07/2011)|
|2.||Lobert, Sharon: 3 articles (06/2011 - 01/2003)|
|3.||Adhikari, Nilanjan: 2 articles (10/2015 - 02/2010)|
|4.||Jha, Tarun: 2 articles (10/2015 - 02/2010)|
|5.||Houghton, Peter J: 2 articles (07/2015 - 08/2013)|
|6.||Kolb, E Anders: 2 articles (07/2015 - 08/2013)|
|7.||Smith, Malcolm A: 2 articles (07/2015 - 08/2013)|
|8.||Gorlick, Richard: 2 articles (07/2015 - 08/2013)|
|9.||Kurmasheva, Raushan T: 2 articles (07/2015 - 08/2013)|
|10.||Maris, John M: 2 articles (07/2015 - 08/2013)|
12/01/2001 - "Whilst these antimitotic drugs are highly effective in the treatment of a number of cancers, both acquired and intrinsic resistance to these agents is a major clinical problem. "
01/01/2014 - "Our results provide a rationale for combining Bcl-xL targeting to antimitotic agents to improve clinical efficacy of antimitotic strategy in cancer therapy. "
01/15/2014 - "The purpose of this study was to identify conditions that increase the sensitivity of resistant cancer cells to antimitotic drugs. "
06/03/2010 - "Our results suggest that budding yeast can be a model to study mitotic cell death in cancer treatment with antimitotic drugs."
12/01/2015 - "Antimitotic drugs in the treatment of cancer."
04/15/2001 - "The authors examined the role of op18 in the sensitivity of human lung carcinoma cells to antimitotic agents. "
03/01/1999 - "The collateral effects of these two antimitotic drugs on MDA-435 human breast carcinoma cells were investigated. "
09/01/1986 - "A human KB carcinoma cell line and a Chinese hamster ovary cell line selected for crossresistance to multiple chemotherapeutic agents, including most antimitotic drugs, are sensitive to DCBT. "
01/01/1983 - "The poor prognosis and efficiency of antimitotic drugs in head and neck carcinomas require analyse of a great number of patients files. "
01/01/1968 - "[Huge and multiple tricho-epithelioma treated partly by excision-graft and local antimitotic agents]."
|3.||Breast Neoplasms (Breast Cancer)
10/01/2015 - "Structural findings of phenylindoles as cytotoxic antimitotic agents in human breast cancer cell lines through multiple validated QSAR studies."
10/15/2001 - "Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study."
10/01/2015 - "Antimitotic agents are potential compounds for the treatment of breast cancer. "
04/15/2008 - "Tryprostatin A is an inhibitor of breast cancer resistance protein, consequently a series of structure-activity studies on the cell cycle inhibitory effects of tryprostatin A analogues as potential antitumor antimitotic agents have been carried out. "
12/01/2008 - "We found that at concentrations that inhibited proliferation and mitosis of MCF7-green fluorescent protein-alpha-tubulin breast tumor cells by approximately 50% (~15 microM), SFN significantly modified microtubule organization in arrested spindles without modulating the spindle microtubule mass, in a manner similar to that of much more powerful antimitotic drugs. "
07/01/1965 - "[Aspects of lymphocytolysis and of lymphatic tissue regeneration in acute experimental poisoning by antimitotic agents]."
11/01/1960 - "[Experimental studies of double poisoning by benzol and antimitotics. "
07/01/2005 - "We examined the mechanism of action of E7389 with purified microtubules and in living cells and found that, unlike antimitotic drugs including vinblastine and paclitaxel that suppress both the shortening and growth phases of microtubule dynamic instability, E7389 seems to work by an end-poisoning mechanism that results predominantly in inhibition of microtubule growth, but not shortening, in association with sequestration of tubulin into aggregates. "
01/01/1989 - "The antimitotic drugs such as colchicine, podophyllotoxin, etc. are currently believed to exert their cytotoxic and antimitotic effects due to binding of the drug-tubulin complex to the growing ends of microtubules (MTs), leading to an "end-capping or poisoning" effect. "
03/01/1985 - "Differentiation characteristics of human neuroblastoma cells in the presence of growth modulators and antimitotic drugs."
06/15/1996 - "In a series of studies using, in turn, neuroblastoma cell lines that express only p75, mutant NGF species that bind selectively to either p75 or trkA, and a polyclonal antibody that binds to the NGF-binding domain of p75, we demonstrate that NGF binding to p75 is both necessary and sufficient for the abrogation of apoptosis in neuroblastoma cells treated with antimitotic agents."
08/01/1986 - "Human neuroblastoma cell lines were also differentially sensitive to antimitotics, especially to vincristine. "
04/01/1986 - "Tetanus toxin binding to neuroblastoma cells differentiated by antimitotic agents."
08/01/1986 - "A 6-day in vitro growth-inhibition assay was used to determine relative sensitivity of six human neuroblastoma cell lines to three classes of cancer chemotherapeutic agents: antimetabolites (methotrexate, methasquin, and cytarabine); antimitotics (vincristine, vinblastine, vindesine, colchicine, and demecolcine); and antibiotics (dactinomycin and doxorubicin). "
|9.||Nerve Growth Factor (NGF)
|1.||Drug Therapy (Chemotherapy)